Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs

Li, Xiaoan; Guo, Tiantian; Qian, Feng; Bai, Tiantian; Wu, Lei; Liu, Yubo; Zheng, Xu; Jia, Jianzhong; Pei, Jin; Wu, Shaoping; Song, Yiming; Zhang, Yongmin

doi:10.1016/j.ejmech.2021.114035

Cited by 19 publications

(19 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In terms of medicine composition, TCM to promote blood circulation and remove blood stasis accounts for a large proportion of CHI for cardio-cerebrovascular diseases, such as Salvia miltiorrhiza, Carthami flos, Panax notoginseng, and Chuanxiong rhizoma (Li et al, 2015a;Sun et al, 2022). Cardiocerebrovascular diseases such as cerebral thrombosis and coronary heart disease are related to enhanced platelet function, blood thickening, and changes in hemodynamic characteristics (Gresele et al, 2021;Li et al, 2022c). In TCM, drugs that promote blood circulation and remove blood stasis dredge blood vessels and eliminate blood stasis, which can change the platelet function and hemodynamics of patients (Li D. et al, 2022).…”

Section: Open Access Edited Bymentioning

confidence: 99%

Chinese herbal injection for cardio-cerebrovascular disease: Overview and challenges

et al. 2023

View full text Add to dashboard Cite

Cardio-cerebrovascular diseases are the leading cause of death worldwide and there is currently no optimal treatment plan. Chinese herbal medicine injection (CHI) is obtained by combining traditional Chinese medicine (TCM) theory and modern production technology. It retains some characteristics of TCM while adding injection characteristics. CHI has played an important role in the treatment of critical diseases, especially cardio-cerebrovascular diseases, and has shown unique therapeutic advantages. TCMs that promote blood circulation and remove blood stasis, such as Salvia miltiorrhiza, Carthami flos, Panax notoginseng, and Chuanxiong rhizoma, account for a large proportion of CHIs of cardio-cerebrovascular disease. CHI is used to treat cardio-cerebrovascular diseases and has potential pharmacological activities such as anti-platelet aggregation, anti-inflammatory, anti-fibrosis, and anti-apoptosis. However, CHIs have changed the traditional method of administering TCMs, and the drugs directly enter the bloodstream, which may produce new pharmacological effects or adverse reactions. This article summarizes the clinical application, pharmacological effects, and mechanism of action of different varieties of CHIs commonly used in the treatment of cardio-cerebrovascular diseases, analyzes the causes of adverse reactions, and proposes suggestions for rational drug use and pharmaceutical care methods to provide a reference for the rational application of CHIs for cardio-cerebrovascular diseases.

show abstract

Section: Open Access Edited Bymentioning

confidence: 99%

Chinese herbal injection for cardio-cerebrovascular disease: Overview and challenges

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Thrombosis is the pathological basis of three major cardiovascular diseases, namely, myocardial infarction, cerebral apoplexy and venous thromboembolism, 1 which are serious threats to human health. 2 , 3 At present, there are two main methods of clinical treatment for thrombosis: drug thrombolysis and interventional surgery. The most commonly used thrombolytic drug is recombinant tissue plasminogen activator (rtPA).…”

Section: Introductionmentioning

confidence: 99%

A Synergistic and Efficient Thrombolytic Nanoplatform: A Mechanical Method of Blasting Combined with Thrombolytic Drugs

Hu¹,

Xu²,

Zhang³

et al. 2022

IJN

View full text Add to dashboard Cite

Background and Objective: Thrombosis is a common disease that poses a great threat to life and health. Most thrombolytic effects of traditional treatments or nanomedicine are not efficient or safe enough. Therefore, we designed a nanoparticle (NP) with a combination of a phase transition material and thrombolytic drugs for efficient and safe thrombolysis. Methods: A thrombus fibrin-targeted and phase transition NP was designed and contained perfluorohexane (PFH) and the thrombolytic drug rtPA core, with CREKA polypeptides attached to the shell of the PLGA NPs. Characterization of the phase transition and ultrasound imaging of the NPs was carried out under low-intensity focused ultrasound (LIFU). LIFU-responsive drug release in vitro was also explored. Under the synergistic effect of PFH and rtPA, the efficient thrombolysis ability of the NPs was studied in vitro and in vivo. In vivo monitoring of thrombosis and biosafety were also verified. Results:The PPrC NPs had good ultrasound imaging ability under LIFU irradiation and were related to the phase transition characteristics of the NPs. CREKA polypeptides can effectively increase the aggregation of the NPs on thrombi. Under static and dynamic conditions in vitro, the "liquid to gas" transformation effect of PFH can perform the destruction function of the excavator at the thrombus site and promote the specific release of rtPA, and the subsequent rtPA drug thrombolysis can further fully dissolve the thrombus. In vivo experiments showed that the NPs can monitor the formation of thrombi and have good thrombolytic effects, with significantly reduced bleeding side effects. The biochemical indexes of the rats were within normal limits after treatment. Conclusion: PPrC NPs loaded with PFH and rtPA combining a mechanical way of blasting with thrombolytic drugs may be a promising new and reliable approach for thrombus monitoring and treatment.

show abstract

“…Thrombosis and other cardiovascular diseases pose a serious threat to human health. 1–3 At present, the number of patients with cardiovascular diseases is still increasing year by year, which was reported as 523 million in 2019 along with 18.6 million deaths. 3,4 Therefore, the effective prevention and treatment of thrombotic diseases is of significant importance.…”

Section: Introductionmentioning

confidence: 99%

“…1–3 At present, the number of patients with cardiovascular diseases is still increasing year by year, which was reported as 523 million in 2019 along with 18.6 million deaths. 3,4 Therefore, the effective prevention and treatment of thrombotic diseases is of significant importance. Currently, despite extensive research on the treatment of end-stage thrombus, 3,5–7 rare effective treatment has been developed focusing on the initial adhesion of platelets to exposed endothelium, which often occurs during atherosclerotic plaque rupture.…”

Section: Introductionmentioning

confidence: 99%

“…3,4 Therefore, the effective prevention and treatment of thrombotic diseases is of significant importance. Currently, despite extensive research on the treatment of end-stage thrombus, 3,5–7 rare effective treatment has been developed focusing on the initial adhesion of platelets to exposed endothelium, which often occurs during atherosclerotic plaque rupture. 8–11 Development of inhibitors targeting the initial adhesion stage in thrombosis is important for the early diagnosis and therapy of thrombosis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Development of antithrombotic peptides based on the molecular interactions between von Willebrand factor and GPIbα

Chen

Zheng

Zhang

2022

Phys. Chem. Chem. Phys.

View full text Add to dashboard Cite

show abstract

Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs

Cited by 19 publications

References 97 publications

Chinese herbal injection for cardio-cerebrovascular disease: Overview and challenges

Chinese herbal injection for cardio-cerebrovascular disease: Overview and challenges

A Synergistic and Efficient Thrombolytic Nanoplatform: A Mechanical Method of Blasting Combined with Thrombolytic Drugs

Development of antithrombotic peptides based on the molecular interactions between von Willebrand factor and GPIbα

Contact Info

Product

Resources

About